We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Paychex Hits 52-Week High, Expanding Customer Base Holds Key
Read MoreHide Full Article
Shares of Paychex, Inc. (PAYX - Free Report) touched a 52-week high of $67.88, eventually closing at $67.31 on Nov 30, 2017. The stock has gained 10.6% year to date, substantially outperforming the 6.1% rally of the industry it belongs to.
The outperformance can be accredited to the company’s expanding customer base and its solid domain expertise in human capital management solutions for payroll, HR, retirement, and insurance services.
Paychex’s sustained focus on investing in product development and enhancing sales force capabilities is helping it to add customers, thereby supporting revenue growth. Notably, revenues witnessed 5-year (2012-2017) CAGR of 7.2%. Higher revenues are likely to expand margins and increase profitability in the long run.
Investors seems to be impressed with Paychex’s latest acquisition of HR Outsourcing Holdings, Inc. (HROI), which has provided it an opportunity to grab market share in the fast growing professional employer organization (PEO) industry. In our opinion, the acquisition is a strategic fit for Paychex as more and more companies are willing to use PEO services rather than creating their in-house HR management departments.
The company’s initiatives to boost revenue growth through acquisitions are encouraging. Since its inception, the company has completed 14 acquisitions. These buyouts have helped Paychex to expand its services as well as global reach, thereby boosting its revenues. Additionally, the industry in which Paychex operates has huge growth potential. The company mainly focuses on small- and mid-sized businesses looking for HR solutions. Paychex has nearly 605,000 payroll clients but the market is still highly untapped. Per the company, there are about 12 million businesses in the United States under its total addressable market, half of which are still untapped.
Nonetheless, the company has been witnessing lower client retention in the last few quarters, which remains a concern for the near term. Also, current political uncertainty may adversely impact outsourcing decision making in the mid-market, thereby affecting Paychex’s overall growth prospect.
Long-term earnings growth for Intel, IPG Photonics and NVIDIA is currently projected to be 8.4%, 19.67% and 11.2% respectively.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Paychex Hits 52-Week High, Expanding Customer Base Holds Key
Shares of Paychex, Inc. (PAYX - Free Report) touched a 52-week high of $67.88, eventually closing at $67.31 on Nov 30, 2017. The stock has gained 10.6% year to date, substantially outperforming the 6.1% rally of the industry it belongs to.
The outperformance can be accredited to the company’s expanding customer base and its solid domain expertise in human capital management solutions for payroll, HR, retirement, and insurance services.
Paychex’s sustained focus on investing in product development and enhancing sales force capabilities is helping it to add customers, thereby supporting revenue growth. Notably, revenues witnessed 5-year (2012-2017) CAGR of 7.2%. Higher revenues are likely to expand margins and increase profitability in the long run.
Investors seems to be impressed with Paychex’s latest acquisition of HR Outsourcing Holdings, Inc. (HROI), which has provided it an opportunity to grab market share in the fast growing professional employer organization (PEO) industry. In our opinion, the acquisition is a strategic fit for Paychex as more and more companies are willing to use PEO services rather than creating their in-house HR management departments.
The company’s initiatives to boost revenue growth through acquisitions are encouraging. Since its inception, the company has completed 14 acquisitions. These buyouts have helped Paychex to expand its services as well as global reach, thereby boosting its revenues.
Additionally, the industry in which Paychex operates has huge growth potential. The company mainly focuses on small- and mid-sized businesses looking for HR solutions. Paychex has nearly 605,000 payroll clients but the market is still highly untapped. Per the company, there are about 12 million businesses in the United States under its total addressable market, half of which are still untapped.
Nonetheless, the company has been witnessing lower client retention in the last few quarters, which remains a concern for the near term. Also, current political uncertainty may adversely impact outsourcing decision making in the mid-market, thereby affecting Paychex’s overall growth prospect.
Zacks Rank & Stocks to Consider
Paychex currently carries a Zacks Rank #3 (Hold).
Intel Corporation (INTC - Free Report) , IPG Photonics Corporation (IPGP - Free Report) and NVIDIA Corporation (NVDA - Free Report) are three better-ranked stocks in the broader technology sector. All of them sport a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth for Intel, IPG Photonics and NVIDIA is currently projected to be 8.4%, 19.67% and 11.2% respectively.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>